Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Background Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2024-07-01
|
| シリーズ: | Journal for ImmunoTherapy of Cancer |
| オンライン･アクセス: | https://jitc.bmj.com/content/12/7/e008837.full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|